Peptide Guide + Calculator
Bremelanotide Reconstitution Calculator & Guide
PT-141 / Vyleesi
Bremelanotide, also known by the development code PT-141, is a melanocortin receptor agonist and the active ingredient in FDA-approved Vyleesi for a narrow hypoactive sexual desire disorder indication in premenopausal women. This guide separates that approved use from broader online claims and explains clinical evidence, safety context, and educational concentration math.
Evidence Snapshot
Bremelanotide research at a glance
Standardized regulatory and evidence context so research compounds, investigational drugs, and approved medications are not treated as if they have the same level of human evidence.
Development / evidence stage
Approved clinical use
Primary mechanism
Cyclic melanocortin receptor agonist used clinically as bremelanotide.
WADA context
No specific prohibition identifiedHuman intervention evidence
Two randomized Phase 3 RECONNECT trials enrolled more than 1,200 premenopausal women and supported FDA approval of Vyleesi for a narrow HSDD indication.
Human biology evidence
Human studies and the RECONNECT clinical program confirm central melanocortin activity relevant to sexual desire and arousal.
Variant matters
FDA-approved Vyleesi is a prefilled autoinjector, not a lyophilized vial. Research-market PT-141 vials are not equivalent to the approved product.
Key takeaway
Bremelanotide has regulatory-grade human evidence for a specific indication, but that approval should not be generalized to broad libido or performance claims.
Evidence labels describe the research base and regulatory context; they are not treatment, dosing, or use recommendations. Review dates describe the last BACToBasics source check for this evidence summary. Anti-doping rules can change and should be verified with the applicable authority.
Bremelanotide Reconstitution Calculator
Enter the vial amount, liquid volume, and amount you want to calculate. BACToBasics will automatically calculate concentration, liquid volume, and U-100 syringe-unit equivalents.
Loading calculator...
Calculator values are educational math inputs only. They are not recommended preparation amounts, doses, or use protocols.
Bremelanotide Reconstitution Math
Reconstitution math starts with the amount contained in the vial and the liquid volume used in the calculation. Dividing the vial amount by the liquid volume gives the resulting concentration.
Example vial amount
10 mg
| Liquid Volume | Calculation | Concentration |
|---|---|---|
| 1 mL | 10 mg ÷ 1 mL | 10 mg/mL |
| 2 mL | 10 mg ÷ 2 mL | 5 mg/mL |
| 3 mL | 10 mg ÷ 3 mL | 3.3333 mg/mL |
This table demonstrates concentration math only. The liquid volumes shown are examples for comparison and are not preparation recommendations.
More Reconstitution Tools
Need to compare different liquid volumes or convert between mg, mcg, mL, and U-100 units? Use the dedicated BACToBasics calculator tools.
What is Bremelanotide / PT-141?
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors. PT-141 was its development code, while Vyleesi is the FDA-approved brand name for bremelanotide injection.
What is Bremelanotide FDA-approved for?
Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women when low desire causes marked distress or interpersonal difficulty and is not explained by another condition, relationship problem, or medication. The FDA label specifically states that it is not indicated for postmenopausal women or men and is not indicated to enhance sexual performance.
What do Phase 3 trials show?
Two randomized, double-blind Phase 3 RECONNECT trials enrolled more than 1,200 women and found statistically significant improvements in sexual-desire scores and reductions in distress related to low desire compared with placebo. These trials support the approved HSDD indication; they do not establish a broad libido or sexual-performance indication for everyone.
How does Bremelanotide work?
Bremelanotide is a melanocortin receptor agonist. Its clinical effect is thought to involve central melanocortin pathways related to sexual desire and arousal rather than the nitric-oxide mechanism used by PDE5 inhibitors. Mechanism alone does not imply the same clinical benefit across sexes or conditions.
Important safety considerations
FDA labeling includes important cardiovascular and tolerability precautions. Bremelanotide can transiently increase blood pressure and reduce heart rate after administration, and Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea, flushing, headache, and injection-site reactions are among the commonly reported adverse effects.
Vyleesi is not a reconstituted vial product
FDA-approved Vyleesi is supplied as a prefilled autoinjector rather than a lyophilized vial that the user reconstitutes. The BACToBasics calculator is therefore only generic educational concentration math for user-entered values and must not be treated as Vyleesi preparation or prescribing instructions.
Explore more about Bremelanotide
7 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Explore more about Bremelanotide
7 linksComparisons, research records, development tracking, blends, and related guides are available here when you want to go deeper.
Related peptide guides
Related guides are ranked from shared comparison pages, shared blend pages, and peptide category rather than a hand-maintained link list.
DSIP guide & calculator
Longevity & Wellness · Delta Sleep-Inducing Peptide / Emideltide
Open →
Peptide guideElamipretide guide & calculator
Longevity & Wellness · SS-31 / Forzinity
Open →
Peptide guideEpitalon guide & calculator
Longevity & Wellness · Synthetic Pineal Tetrapeptide
Open →
Peptide guideMOTS-C guide & calculator
Longevity & Wellness · Mitochondrial-Derived Peptide
Open →
Relevant glossary concepts
Definitions are matched against the guide's structured title, subtitle, description, and educational sections.
FDA-Approved
A status indicating that the FDA has approved a specific drug product for one or more labeled uses after reviewing the required evidence and manufacturing information.
Open →
GlossaryAgonist
A molecule that binds to a receptor and activates signaling through that receptor.
Open →
GlossaryConcentration
The amount of a substance contained in a given volume of liquid, such as mg/mL or mcg/mL.
Open →
Bremelanotide FAQ
Tap a question to expand only the answer you want to read.
Is PT-141 the same as Bremelanotide?
Yes. PT-141 was the development code for bremelanotide. Vyleesi is the FDA-approved brand name.
Is Bremelanotide FDA-approved?
Yes, but only for a specific indication: acquired, generalized HSDD in premenopausal women who meet the labeled criteria.
Is Vyleesi approved for men?
No. FDA labeling states that Vyleesi is not indicated for treatment of HSDD in men.
Is Bremelanotide approved to enhance sexual performance?
No. The FDA label explicitly states that Vyleesi is not indicated to enhance sexual performance.
What are common Bremelanotide side effects?
Nausea is common, and flushing, headache, vomiting, and injection-site reactions have also been reported. The FDA label also includes blood-pressure and cardiovascular precautions.
Sources & References
3 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Sources & References
3 sourcesOpen the references when you want to inspect the research and regulatory sources behind this guide.
Official labeling for indication, limitations of use, cardiovascular precautions, and adverse effects.
Two randomized Phase 3 trials evaluating bremelanotide for HSDD in premenopausal women.
FDA substance record linking the development code PT-141 with bremelanotide and Vyleesi.
BACToBasics provides educational information and math tools only. This content is not medical advice, dosing advice, injection instruction, or a recommendation to use any peptide or medication.